Literature DB >> 30857843

Short and long-term changes in platelet and inflammatory biomarkers after cryoballoon and radiofrequency ablation.

Khalid Bin Waleed1, Xiaomeng Yin2, Xiaolei Yang2, Bailing Dai2, Yang Liu2, Zhao Wang2, Xumin Guan2, Lianjun Gao2, De Greef Yves3, Lili Wang4, Gary Tse5, Riccardo Cappato6, Shulin Wu7, Yunlong Xia8.   

Abstract

BACKGROUND: Cryoballoon (CB) versus radiofrequency (RF) ablation response on prothrombotic biomarkers obtained different results at short-term, while long-term is still unknown in atrial fibrillation (AF) treatment. We evaluated short and long-term changes in platelet and inflammatory biomarkers after CB and RF ablation.
METHODS: Fifty-eight paroxysmal AF patients were randomized for pulmonary vein (PV) isolation using either CB (n = 29) or RF (n = 29) ablation. Biomarkers of platelet activation [P-selectin (CD62P), CD40 ligand (CD40L), platelet factor-4 (PF-4), mean platelet volume (MPV), platelet-leukocyte ratio (P-LCR), and platelet distribution width (PDW)]; and inflammatory [high sensitivity CRP (hs-CRP) and interleukin-6 (IL-6)] were measured at baseline, 18-24 h and 6-Months postablation.
RESULTS: Twenty-four (86.2%) and twenty-six (89.7%) patients remained in sinus rhythm at 6-Months in CB and RF group respectively (p = 0.500). After 18-24 h postablation, CD62P, CD40L, PF-4, hs-CRP, and IL-6 levels were significantly activated in both groups (p < 0.001). However, CD62P was significantly lower in CB than RF (p = 0.017). At 6-Month postablation in CB group, all platelet biomarkers CD62P (p = 0.021), CD40L (p < 0.001), PF-4 (p < 0.001), MPV (p = 0.010), PDW (p = 0.004), and P-LCR (p = 0.033) were significantly decreased compared to baseline levels. However in RF group, CD40L and PF-4 (p < 0.001) significant decreased, CD62P (p = 0.022) increased, and no change in MPV and P-LCR (p > 0.05) compared to baseline levels. hs-CRP and IL-6 levels were comparable between baseline and 6-Months in both groups (p > 0.05).
CONCLUSIONS: CB ablation might influence the risk of thromboembolism due to less platelet activation after PV isolation and decreased platelet activation at long-term in maintained sinus rhythm patients compared to RF.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Atrial fibrillation; Biomarkers; Cryoballoon; Inflammatory; Platelet; Radiofrequency

Mesh:

Substances:

Year:  2019        PMID: 30857843     DOI: 10.1016/j.ijcard.2019.02.054

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  4 in total

1.  Catheter ablation versus antiarrhythmic drugs with risk factor modification for treatment of atrial fibrillation: a protocol of a randomised controlled trial (PRAGUE-25 trial).

Authors:  Pavel Osmancik; Štěpán Havránek; Veronika Bulková; Jan Chovančík; Tomáš Roubíček; Dalibor Heřman; Zuzana Čarná; Vladimír Tuka; Martin Matoulek; Martin Fiala; Otakar Jiravský; Sylvie Stregl-Hruskova; Adam Latiňák; Jiřina Kotryová; Jiří Jarkovský
Journal:  BMJ Open       Date:  2022-06-15       Impact factor: 3.006

Review 2.  Economic Evaluation of Catheter Ablation Versus Medical Therapy for the Treatment of Atrial Fibrillation from the Perspective of the UK.

Authors:  Lisa Wm Leung; Zaki Akhtar; Christos Kontogiannis; Ryan J Imhoff; Hannah Taylor; Mark M Gallagher
Journal:  Arrhythm Electrophysiol Rev       Date:  2022-04

3.  Data for short and long-term prothrombotic biomarkers after cryoballoon and radiofrequency ablation.

Authors:  Khalid Bin Waleed; Lili Wang; Gary Tse; Xiaomeng Yin; Xiaolei Yang; Bailing Dai; Yang Liu; Zhao Wang; Xumin Guan; Lianjun Gao; De Greef Yves; Riccardo Cappato; Shulin Wu; Yunlong Xia
Journal:  Data Brief       Date:  2019-06-05

4.  Cost-effectiveness of catheter ablation versus medical therapy for the treatment of atrial fibrillation in the United Kingdom.

Authors:  Lisa W M Leung; Ryan J Imhoff; Howard J Marshall; Diana Frame; Peter J Mallow; Laura Goldstein; Tom Wei; Maria Velleca; Hannah Taylor; Mark M Gallagher
Journal:  J Cardiovasc Electrophysiol       Date:  2021-12-16       Impact factor: 2.942

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.